The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
The US Senate’s vote to approve the revised US-Mexico-Canada trade agreement has been welcomed by the country’s Association for Accessible Medicines.
Having been passed by a vote of 89-10 in the Senate – following a 385-41 vote in the House of Representatives – the legislation is now ready to be signed into law in the US
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
